Study | Intervention | Number of response | Number of patients | ORR (%) | OR | 95% CI | P value |
---|---|---|---|---|---|---|---|
Right-sided colorectal cancer | |||||||
 PRIME [20] | FOLFOX + panitumumab FOLFOX | 16 16 | 38 46 | 42.1 34.8 | 1.364 | 0.56–3.30 | 0.492 |
 TAILOR [21] | FOLFOX + cetuximab FOLFOX | 20 9 | 45 38 | 44.4 23.7 | 2.578 | 0.99–6.67 | 0.051 |
 CRYSTAL [22] | FOLFIRI + cetuximab FOLFIRI | 1417 | 3351 | 42.4 33.3 | 1.474 | 0.60–3.64 | 0.4 |
 MACRO-2/PLANET [25] | FOLFIRI/FOLFOX + panitumumab | 11 | 33 | 33.3 | – | – | – |
 VOLFI [23] | FOLFOXIRI + panitumumab FOLFOXIRI | 6 3 | 10 8 | 60 37.5 | 2.500 | 0.37–16.88 | 0.347 |
 PEAK [20] | FOLFOX + panitumumab FOLFOX + bevacizumab | 14 7 | 22 14 | 63.6 50.0 | 1.75 | 0.45–6.83 | 0.42 |
 FIRE-3 [24] | FOLFIRI + cetuximab FOLFIRI + bevacizumab | 18 19 | 30 38 | 60.0 50.0 | 1.500 | 0.57–3.95 | 0.412 |
 CALGB80405 [13] | FOLFIRI/FOLFOX + cetuximab FOLFIRI/FOLFOX + bevacizumb | 30 31 | 71 78 | 42.3 39.7 | 1.109 | 0.58–2.13 | 0.756 |
Left-sided colorectal cancer | |||||||
 PRIME [20] | FOLFOX + panitumumab FOLFOX | 114 82 | 168 156 | 67.9 52.6 | 1.905 | 1.21–2.99 | 0.005 |
 TAILOR [21] | FOLFOX + cetuximab FOLFOX | 97 70 | 146 162 | 66.4 43.2 | 2.602 | 1.63–4.13 | < 0.001 |
 CRYSTAL [22] | FOLFIRI + cetuximab FOLFIRI | 103 56 | 142 138 | 72.5 40.6 | 3.867 | 2.34–6.38 | < 0.001 |
 MACRO-2/PLANET [25] | FOLFIRI/FOLFOX + panitumumab | 78 | 148 | 52.7 | – | – | – |
 VOLFI [23] | FOLFOXIRI + panitumumab FOLFOXIRI | 48 17 | 53 25 | 90.6 68 | 4.518 | 1.30–15.72 | 0.018 |
 PEAK [20] | FOLFOX + panitumumab FOLFOX + bevacizumab | 34 31 | 53 54 | 64.1 57.4 | 1.328 | 0.61–2.89 | 0.476 |
 FIRE-3 [24] | FOLFIRI + cetuximab FOLFIRI + bevacizumab | 93 78 | 124 133 | 75.0 58.6 | 2.115 | 1.24–3.60 | 0.006 |
 CALGB80405 [13] | FOLFIRI/FOLFOX + cetuximab FOLFIRI/FOLFOX + bevacizumb | 120 88 | 173 152 | 69.4 57.9 | 1.647 | 1.04–2.60 | 0.032 |